Market Overview:
The global Meniere's disease drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Meniere's disease, rising awareness about Meniere's disease and its treatment options, and technological advancements in the field of Meniere's disease drugs. The global Meniere's disease drugs market is segmented on the basis of type into motion sickness medication, anti-nausea medication, and others. On the basis of application, it is segmented into hospitals, clinics, medical research centers, and others. Geographically it is segmented into North America (U.S., Canada), Latin America (Mexico), Europe (Germany), Asia Pacific (Japan) Middle East & Africa (South Africa).
Product Definition:
Meniere's disease drugs are used to treat the symptoms of Meniere's disease. These drugs can help to reduce the amount of fluid in the inner ear, which can help to relieve some of the symptoms.
Motion Sickness Medication:
Motion sickness is a type of motion sensitivity, which occurs when the visual system is affected by moving stimuli. It can be due to otoscopic (ear, eye and nose related) or somatic (body related) causes. The most common symptoms associated with it are nausea and vomiting.
Anti-Nausea Medication:
Anti-nausea medication is used to prevent or reduce nausea and vomiting. Vomiting can be caused by several factors such as motion sickness, eating, drinking, and drugs. Medication for meniere's disease works by changing the way the brain and nervous system respond to certain chemicals in the body (serotonin). Anti-nausea medications are not usually recommended during pregnancy because of possible harm to the baby.
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and medical research centers, and others. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities for Meniere's patients. In addition to providing treatment for menière's disease, these hospitals offer care for ear infections & hearing loss as well as other ENT problems.
Meniere's disease occurs predominantly in middle-aged people between 30-50 years of age which is a key factor contributing towards hospitalization being the most preferred method of treatment among all age groups across the globe.
Regional Analysis:
Europe dominated the global market in terms of revenue share in 2017. The presence of a large number of Meniere's disease patients and favorable reimbursement policies are some factors contributing to its largest share. In addition, the European region is one of the top destinations for medical tourism due to its high quality healthcare services at affordable costs. This factor is also expected to drive growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising disposable income, increasing awareness about early diagnosis, and availability & adoption rate of meniere's disease treatment options at low cost in this region as compared to developed regions such as Europe & North America. Moreover, Asia Pacific has become a hub for drug manufacturing with many major pharmaceutical companies setting up their production facilities here due mainly on lower labor costs along with other factors mentioned above (availability & adoption rate).
Growth Factors:
- Increasing prevalence of Meniere's Disease
- Growing awareness about Meniere's Disease and its treatment options
- Rising demand for better and more effective treatments for Meniere's Disease
- Availability of novel drugs and therapies for the treatment of Meniere's Disease
- Growing number of clinical studies on the efficacy of new drugs and therapies for the treatment of Meniere's Disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Meniere's Disease Drugs Market Research Report
By Type
Motion Sickness Medication, Anti-Nausea Medication, Others
By Application
Hospitals, Clinics, Medical Research Centers, Others
By Companies
Roche, Novartis, Pfizer, Auris Medical, Jubilant Cadista, Otonomy, Sound Pharmaceuticals, WellSpring Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Meniere's Disease Drugs Market Report Segments:
The global Meniere's Disease Drugs market is segmented on the basis of:
Types
Motion Sickness Medication, Anti-Nausea Medication, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Medical Research Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Novartis
- Pfizer
- Auris Medical
- Jubilant Cadista
- Otonomy
- Sound Pharmaceuticals
- WellSpring Pharmaceutical
Highlights of The Meniere's Disease Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Motion Sickness Medication
- Anti-Nausea Medication
- Others
- By Application:
- Hospitals
- Clinics
- Medical Research Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Meniere's Disease Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There are a number of medications used to treat Meniere's Disease. These medications can help to reduce the frequency and severity of episodes, as well as improve overall quality of life. Some common drugs used to treat Meniere's Disease include: - Antidepressants (such as fluoxetine or paroxetine) - Ototoxic drugs (such as aminoglycosides or amphotericin B) - Antiarrhythmic drugs (such as amiodarone or sotalol)
Some of the major players in the meniere's disease drugs market are Roche, Novartis, Pfizer, Auris Medical, Jubilant Cadista, Otonomy, Sound Pharmaceuticals, WellSpring Pharmaceutical.
The meniere's disease drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Meniere's Disease Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Meniere's Disease Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Meniere's Disease Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Meniere's Disease Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Meniere's Disease Drugs Market Size & Forecast, 2020-2028
4.5.1 Meniere's Disease Drugs Market Size and Y-o-Y Growth
4.5.2 Meniere's Disease Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Motion Sickness Medication
5.2.2 Anti-Nausea Medication
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Medical Research Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Meniere's Disease Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Meniere's Disease Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Motion Sickness Medication
9.6.2 Anti-Nausea Medication
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Medical Research Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Motion Sickness Medication
10.6.2 Anti-Nausea Medication
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Medical Research Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Motion Sickness Medication
11.6.2 Anti-Nausea Medication
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Medical Research Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Motion Sickness Medication
12.6.2 Anti-Nausea Medication
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Medical Research Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Motion Sickness Medication
13.6.2 Anti-Nausea Medication
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Medical Research Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Meniere's Disease Drugs Market: Competitive Dashboard
14.2 Global Meniere's Disease Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Novartis
14.3.3 Pfizer
14.3.4 Auris Medical
14.3.5 Jubilant Cadista
14.3.6 Otonomy
14.3.7 Sound Pharmaceuticals
14.3.8 WellSpring Pharmaceutical
